The International Cancer Research Partnership
NCRI is a member of the International Cancer Research Partnership (ICRP), which includes cancer research funders from USA, Canada, Europe, Japan and Australia. The ICRP is a unique alliance of cancer organisations working together to enhance global collaboration and strategic coordination of research. The group operates through regular teleconferences and annual face-to-face meetings, as well as publishing portfolio analyses and evaluation reports.
NCRI regularly participates in activities led by the European Union, including TRANSCAN which is a collaborative network of ministries, funding agencies and research councils with programmes in translational cancer research. Through Cancer Research UK as the formal partner, NCRI has been leading a work package aimed at analysing the cancer research portfolio of funders across as many European countries as possible.
International Rare Cancers Initiative
UK funders and experts have been instrumental in the setting up and running of the International Rare Cancers Initiative (IRCI). Through being able to draw on a wider base of patients than is available in any one country, and the use of innovative methodology, IRCI aims to boost progress on new treatments for rare cancers. Other partners include the European Organisation for Research and Treatment of Cancer (EORTC) and the US National Cancer Institute (NCI).
International Cancer Genome Consortium
A number of NCRI Partners participate in the International Cancer Genome Consortium (ICGC), whose overall goal is to obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumour types and/or subtypes which are of clinical and societal importance across the globe.